MayoComplete Solid Tumor Panel: Kevin C. Halling, M.D., Ph.D.
Kevin C. Halling, M.D., Ph.D., co-director of Mayo Clinic’s Genomics Lab, discusses the MayoComplete Solid Tumor Panel, a next-generation sequencing assay that assesses for mutations in 514 genes shown to have clinical significance. Utilizing a hybrid cap
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
(00:31):
Before we get started, Dr. Halling, could you provide us with a little bit about you and your background?
(01:11):
Would you like to give us a basic summary of this test?
(02:43):
So in talking about patients, can you tell us which patients should have this testing? And when it is typically performed?
(05:01):
Do you want to talk about some of the guidelines that were used to shape the genes included in this panel?
(05:36):
Can you tell us a bit about the alternative test options that are available and how they compare to this large panel?
(06:42):
So I know most other panels on the market assess for mutations and fusions. Is there a reason why our panel also looks at amplifications and are certain subset of the genes?
(07:29):
So do you want to talk about how this panel offers some benefits over other large panels in the market?
(08:46):
Let's talk a little bit about how the results of this test can be used in patient care.